T. Rowe Price Investment Management, Inc. Madrigal Pharmaceuticals, Inc. Transaction History
T. Rowe Price Investment Management, Inc.
- $163 Billion
- Q1 2024
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 42,986 shares of MDGL stock, worth $11.9 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
42,986Holding current value
$11.9 Million% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding MDGL
# of Institutions
315Shares Held
20MCall Options Held
824KPut Options Held
1.04M-
Janus Henderson Group PLC London, X02.6MShares$719 Million0.39% of portfolio
-
Baker Bros. Advisors LP New York, NY1.97MShares$545 Million6.66% of portfolio
-
Avoro Capital Advisors LLC New York, NY1.94MShares$538 Million6.26% of portfolio
-
John Paulson Paulson & Co. Inc. | New York, Ny1.78MShares$491 Million34.28% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.67MShares$462 Million0.01% of portfolio
About MADRIGAL PHARMACEUTICALS, INC.
- Ticker MDGL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 17,103,400
- Market Cap $4.73B
- Description
- Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...